SCHEMBL5047535

SCHEMBL5047535

CCCCCCSc1nc(C)cc(CN2CCCC(C(N)=O)C2)n1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BCHE P06276 5/20 0.51
GAA P10253 1/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
S1PR5 Q9H228 2/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045981 0.85 ALDH1A1 (0.38) GAAKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL5045769 0.81 SMN1; SMN2 (0.43) GAAKMT2AMEN1MAPTL3MBTL1
SCHEMBL5047621 0.81 GAA (0.38) GAAKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL5049973 0.80 SMN1; SMN2 (0.43) GAAKMT2AMEN1MAPTL3MBTL1
SCHEMBL5047348 0.80 SMN1; SMN2 (0.43) GAAKMT2AMEN1MAPTL3MBTL1
SCHEMBL5045848 0.79 GAA (0.37) GAAKMT2AMEN1MAPTLMNA
SCHEMBL5047449 0.79 SPHK1 (0.40) GAAKMT2AMEN1MAPTL3MBTL1
SCHEMBL5043424 0.78 THRB (0.48) GAAKMT2AMEN1MAPTNPSR1
SCHEMBL5046056 0.77 HTT (0.37) GAAMAPTL3MBTL1SMN1; SMN2HSD17B10
SCHEMBL5049995 0.76 SMN1; SMN2 (0.43) GAAMAPTLMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US claimed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US claimed
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
EP-1725239-A1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2005094828-A1 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 BCHE 1191/4885GAA 1891/4885KMT2A 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.